Literature DB >> 20445561

B-cell maturation and antibody responses in individuals carrying a mutated CD19 allele.

H Artac1, I Reisli, R Kara, I Pico-Knijnenburg, S Adin-Çinar, S Pekcan, C M Jol-van der Zijde, M J D van Tol, L E Bakker-Jonges, J J M van Dongen, M van der Burg, M C van Zelm.   

Abstract

Homozygous CD19 mutations lead to an antibody deficiency due to disruption of the CD19 complex and consequent impaired signaling by the B-cell antigen receptor. We studied the effects of heterozygous CD19 mutations on peripheral B-cell development and antibody responses in a large family with multiple consanguineous marriages. Sequence analysis of 96 family members revealed 30 carriers of the CD19 mutation. Lymphocyte subset counts were not significantly different between carriers and noncarriers in three different age groups (0-10 years; 11-18 years; adults). B cells of carriers had reduced CD19 and CD21 median expression levels, and had reduced proportions of transitional (0-10 years) and CD5(+) B cells (adults). CD19 carriers did not show clinical signs of immunodeficiency; they were well capable to produce normal serum Ig levels and had normal responses to primary and booster vaccinations. The frequency of mutated Vκ alleles was not affected. Heterozygous loss of CD19 causes some changes in the naive B-cell compartment, but overall in vivo B-cell maturation or humoral immunity is not affected. Many antibody deficiencies are not monogenetic, but likely caused by a combination of multiple genetic variations. Therefore, functional analyses of immune cell function should be carried out to show whether heterozygous mutations contribute to disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20445561     DOI: 10.1038/gene.2010.22

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  12 in total

1.  CD19 controls Toll-like receptor 9 responses in human B cells.

Authors:  Henner Morbach; Jean-Nicolas Schickel; Charlotte Cunningham-Rundles; Mary Ellen Conley; Ismail Reisli; Jose Luis Franco; Eric Meffre
Journal:  J Allergy Clin Immunol       Date:  2015-10-21       Impact factor: 10.793

2.  Age-related alterations of the CD19 complex and memory B cells in children with Down syndrome.

Authors:  Ayse Nazli Seckin; Hulya Ozdemir; Ayca Ceylan; Hasibe Artac
Journal:  Clin Exp Med       Date:  2017-02-14       Impact factor: 3.984

3.  Reduced CD19 expression and decreased memory B cell numbers in transient hypogammaglobulinemia of infancy.

Authors:  Hasibe Artac; Reyhan Kara; Bahar Gokturk; Ismail Reisli
Journal:  Clin Exp Med       Date:  2012-07-21       Impact factor: 3.984

4.  Cryo-EM structure of the B cell co-receptor CD19 bound to the tetraspanin CD81.

Authors:  Katherine J Susa; Shaun Rawson; Andrew C Kruse; Stephen C Blacklow
Journal:  Science       Date:  2021-01-15       Impact factor: 47.728

Review 5.  New frontiers of primary antibody deficiencies.

Authors:  Mirjam van der Burg; Menno C van Zelm; Gertjan J A Driessen; Jacques J M van Dongen
Journal:  Cell Mol Life Sci       Date:  2011-11-01       Impact factor: 9.261

6.  Agammaglobulinemia associated with BCR⁻ B cells and enhanced expression of CD19.

Authors:  A Kerry Dobbs; Amma Bosompem; Elaine Coustan-Smith; Gayle Tyerman; Frank T Saulsbury; Mary Ellen Conley
Journal:  Blood       Date:  2011-06-21       Impact factor: 22.113

7.  Reference values for B-cell surface markers and co-receptors associated with primary immune deficiencies in healthy Turkish children.

Authors:  Elif Azarsiz; Neslihan Edeer Karaca; Guzide Aksu; Necil Kutukculer
Journal:  Int J Immunopathol Pharmacol       Date:  2017-04-28       Impact factor: 3.219

8.  Common variable immune deficiency in children--clinical characteristics varies depending on defect in peripheral B cell maturation.

Authors:  Barbara Piątosa; Małgorzata Pac; Katarzyna Siewiera; Barbara Pietrucha; Maja Klaudel-Dreszler; Edyta Heropolitańska-Pliszka; Beata Wolska-Kuśnierz; Hanna Dmeńska; Hanna Gregorek; Irena Sokolnicka; Aneta Rękawek; Katarzyna Tkaczyk; Ewa Bernatowska
Journal:  J Clin Immunol       Date:  2013-02-07       Impact factor: 8.317

Review 9.  Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.

Authors:  Henrik E Mei; Stefanie Schmidt; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2012-11-08       Impact factor: 5.156

Review 10.  "Immune TOR-opathies," a Novel Disease Entity in Clinical Immunology.

Authors:  Sophie Jung; Laura Gámez-Díaz; Michele Proietti; Bodo Grimbacher
Journal:  Front Immunol       Date:  2018-05-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.